Drugs / CS-2034
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05373485 | May → Aug 2022 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05373472 | Jul → Sep 2022 | COVID-19 | CanSino Biologics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-02-20 | CanSino Biologics Inc. | Results Latest Study Shows Encouraging Results of CanSinoBIO’s mRNA COVID-19 Vaccine as Heterologous Booster cansinotech.com ↗
The results of the study indicated that heterologous boosting with CS-2034 induced higher levels of immune responses against different SARS-CoV-2 variants, and provided better protection against Omicron infection than homologous boosting in adults aged 18 and above, who have received three prior doses of inactivated COVID-19 vaccine. |
| 2023-01-05 | CanSino Biologics Inc. | Results CanSinoBIO Announces Encouraging Clinical Progress of its COVID-19 mRNA Vaccine cansinotech.com ↗
The safety analysis showed that 28 days post booster vaccination, the overall incidence of adverse events was mainly mild in severity. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-20 | CanSino Biologics Inc. | Latest Study Shows Encouraging Results of CanSinoBIO’s mRNA COVID-19 Vaccine as Heterologous Booster cansinotech.com ↗ |
| 2023-01-05 | CanSino Biologics Inc. | CanSinoBIO Announces Encouraging Clinical Progress of its COVID-19 mRNA Vaccine cansinotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-2034 | “We aimed to evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine (CS-2034, CanSino, Shanghai, China) in adults without COVID-19 infection from China.” PMID 37898410 ↗ Oct 20231“The vaccine CS-2034 was well tolerated, with adverse reactions largely mild to moderate and comparable across dose groups.” PMID 41267026 ↗ Nov 2025 |
| Known as | COVID-19 mRNA vaccine | “Our objective was to evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine (CS-2034) in Chinese adults, and to determine the optimal dosage with a favorable...” PMID 41267026 ↗ Nov 2025 |
| Modality | Messenger RNA (mRNA) | “COVID-19 mRNA vaccine (CS-2034)” PMID 41267026 ↗ Nov 2025 |